Skip to main content
Fig. 1 | BMC Neurology

Fig. 1

From: Does the 5–2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5–2-1-positive patients in 7 countries

Fig. 1

Measures of clinical burden in 5–2-1-positive patients compared with 5–2-1-negative patients. *p < 0.0001. 5–2-1, taking ≥5 doses of oral levodopa/day, OR having ≥2 h ‘off’-time/waking day, OR having ≥1 h troublesome dyskinesia/waking day. ADL, activities of daily living; MMSE, Mini-Mental State Examination; PD, Parkinson’s disease; UPDRS, Unified Parkinson’s Disease Rating Scale

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us